Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 80

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 80
---
 as Japan, China, India; increasing demand for eye care services; improved diagnostics; rising healthcare expenditure; and expanding penetration of therapies which in the past may have been less widely available. Alternatively, challenges include variability in access, reimbursement, and affordability across countries.

Middle East & Africa / Latin America: These regions currently represent smaller shares of the global market (for example, the Middle East is estimated at only ~2% of global AMD treatment revenue in 2025 per one source) but are projected to grow at higher rates (e.g., ~10.5% CAGR in the Middle East) as healthcare systems strengthen and awareness rises.

Key growth drivers and constraints

Drivers:

| ● | Ageing                                                                                          
 populations worldwide mean more patients with AMD, increasing treatment demand                  |
| ● | Technological                                                                                   
 & therapeutic innovation: new treatment modalities (gene therapies, sustained release)          
 create growth beyond legacy therapies.                                                          |
| ● | Improved                                                                                        
 access & diagnostics in emerging markets: as more patients are diagnosed early and seek         
 treatment, penetration rises.                                                                   |
| ● | Shift                                                                                           
 toward hospitals and specialist care settings, which may increase uptake of advanced therapies. |

Constraints/challenges:

| ● | High                                                                                               
 cost of therapies: many AMD treatments are expensive, and in non-US markets reimbursement/coverage 
 may lag.                                                                                           |
| ● | Variability                                                                                        
 in healthcare infrastructure and access: in less developed regions or rural areas, access          
 to retinal specialists or regular intravitreal injections may be limited.                          |

| 46 |

| ● | Market                                                                                       
 saturation in developed regions for standard therapies: in Europe and developed Asia Pacific 
 markets, many patients may already be treated, so further growth depends on breakthrough     
 therapies or expanding indications.                                                          |
| ● | Regulatory                                                                                   
 and reimbursement hurdles for novel therapies: especially in markets with tighter budget     
 constraints, adoption of new modalities may be slower.                                       |

Implications & outlook for non-US markets

For companies, non-US markets present both mature (e.g., Europe, Japan) and emerging (Asia-Pacific, Latin America, Middle East) opportunities. In mature markets, the emphasis will be on differentiation — offering therapies with fewer injections, longer intervals, better outcomes, or improved convenience. In emerging markets, the emphasis will be on access — making therapies affordable, strengthening diagnostics, expanding specialist networks, and addressing underserved patient populations.

From a strategic viewpoint, supply chain, pricing strategy, reimbursement negotiation, localization (e.g., country-specific clinical